|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ENPP1 |
Gene summary for ENPP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ENPP1 | Gene ID | 5167 |
| Gene name | ectonucleotide pyrophosphatase/phosphodiesterase 1 | |
| Gene Alias | ARHR2 | |
| Cytomap | 6q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0000271 | UniProtAcc | P22413 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5167 | ENPP1 | NAFLD1 | Human | Liver | NAFLD | 1.50e-10 | 7.75e-01 | -0.04 |
| 5167 | ENPP1 | S41 | Human | Liver | Cirrhotic | 1.47e-02 | 4.81e-01 | -0.0343 |
| 5167 | ENPP1 | S43 | Human | Liver | Cirrhotic | 3.53e-03 | -9.79e-02 | -0.0187 |
| 5167 | ENPP1 | HCC1_Meng | Human | Liver | HCC | 1.55e-47 | -5.76e-02 | 0.0246 |
| 5167 | ENPP1 | HCC2_Meng | Human | Liver | HCC | 3.41e-03 | -1.58e-01 | 0.0107 |
| 5167 | ENPP1 | cirrhotic1 | Human | Liver | Cirrhotic | 3.22e-03 | -1.70e-01 | 0.0202 |
| 5167 | ENPP1 | HCC1 | Human | Liver | HCC | 1.37e-22 | 4.30e+00 | 0.5336 |
| 5167 | ENPP1 | HCC2 | Human | Liver | HCC | 2.23e-11 | 3.59e+00 | 0.5341 |
| 5167 | ENPP1 | Pt14.a | Human | Liver | HCC | 4.66e-03 | 2.94e-01 | 0.0169 |
| 5167 | ENPP1 | male-WTA | Human | Thyroid | PTC | 9.36e-04 | -4.21e-02 | 0.1037 |
| 5167 | ENPP1 | PTC01 | Human | Thyroid | PTC | 5.59e-03 | -9.17e-02 | 0.1899 |
| 5167 | ENPP1 | PTC04 | Human | Thyroid | PTC | 4.99e-08 | 1.77e-01 | 0.1927 |
| 5167 | ENPP1 | PTC05 | Human | Thyroid | PTC | 2.27e-05 | 3.23e-01 | 0.2065 |
| 5167 | ENPP1 | PTC06 | Human | Thyroid | PTC | 4.11e-10 | 2.77e-02 | 0.2057 |
| 5167 | ENPP1 | PTC07 | Human | Thyroid | PTC | 2.24e-12 | -7.08e-02 | 0.2044 |
| 5167 | ENPP1 | ATC09 | Human | Thyroid | ATC | 1.69e-07 | 8.88e-02 | 0.2871 |
| 5167 | ENPP1 | ATC12 | Human | Thyroid | ATC | 1.08e-06 | -1.13e-01 | 0.34 |
| 5167 | ENPP1 | ATC13 | Human | Thyroid | ATC | 8.39e-52 | 1.14e+00 | 0.34 |
| 5167 | ENPP1 | ATC1 | Human | Thyroid | ATC | 2.09e-07 | 1.24e-01 | 0.2878 |
| 5167 | ENPP1 | ATC2 | Human | Thyroid | ATC | 9.97e-06 | 7.47e-01 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00194396 | Liver | NAFLD | aromatic compound catabolic process | 102/1882 | 467/18723 | 2.29e-14 | 1.91e-11 | 102 |
| GO:19013616 | Liver | NAFLD | organic cyclic compound catabolic process | 105/1882 | 495/18723 | 7.04e-14 | 5.15e-11 | 105 |
| GO:00442707 | Liver | NAFLD | cellular nitrogen compound catabolic process | 93/1882 | 451/18723 | 1.04e-11 | 4.34e-09 | 93 |
| GO:00467006 | Liver | NAFLD | heterocycle catabolic process | 92/1882 | 445/18723 | 1.16e-11 | 4.52e-09 | 92 |
| GO:00713755 | Liver | NAFLD | cellular response to peptide hormone stimulus | 65/1882 | 290/18723 | 3.95e-10 | 9.62e-08 | 65 |
| GO:00346556 | Liver | NAFLD | nucleobase-containing compound catabolic process | 80/1882 | 407/18723 | 3.07e-09 | 4.61e-07 | 80 |
| GO:19016536 | Liver | NAFLD | cellular response to peptide | 71/1882 | 359/18723 | 1.82e-08 | 2.09e-06 | 71 |
| GO:00328695 | Liver | NAFLD | cellular response to insulin stimulus | 47/1882 | 203/18723 | 3.60e-08 | 3.63e-06 | 47 |
| GO:00434346 | Liver | NAFLD | response to peptide hormone | 76/1882 | 414/18723 | 1.51e-07 | 1.09e-05 | 76 |
| GO:00092596 | Liver | NAFLD | ribonucleotide metabolic process | 72/1882 | 385/18723 | 1.51e-07 | 1.09e-05 | 72 |
| GO:00160495 | Liver | NAFLD | cell growth | 85/1882 | 482/18723 | 1.75e-07 | 1.25e-05 | 85 |
| GO:00196936 | Liver | NAFLD | ribose phosphate metabolic process | 73/1882 | 396/18723 | 2.23e-07 | 1.53e-05 | 73 |
| GO:00059965 | Liver | NAFLD | monosaccharide metabolic process | 53/1882 | 257/18723 | 2.89e-07 | 1.92e-05 | 53 |
| GO:00091177 | Liver | NAFLD | nucleotide metabolic process | 85/1882 | 489/18723 | 3.31e-07 | 2.18e-05 | 85 |
| GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
| GO:00620125 | Liver | NAFLD | regulation of small molecule metabolic process | 63/1882 | 334/18723 | 6.55e-07 | 3.79e-05 | 63 |
| GO:00067537 | Liver | NAFLD | nucleoside phosphate metabolic process | 85/1882 | 497/18723 | 6.69e-07 | 3.83e-05 | 85 |
| GO:00328685 | Liver | NAFLD | response to insulin | 53/1882 | 264/18723 | 6.99e-07 | 3.95e-05 | 53 |
| GO:00060917 | Liver | NAFLD | generation of precursor metabolites and energy | 84/1882 | 490/18723 | 7.03e-07 | 3.95e-05 | 84 |
| GO:00193185 | Liver | NAFLD | hexose metabolic process | 49/1882 | 237/18723 | 7.41e-07 | 4.12e-05 | 49 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01232 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
| hsa00770 | Liver | Cirrhotic | Pantothenate and CoA biosynthesis | 13/2530 | 21/8465 | 2.32e-03 | 9.90e-03 | 6.10e-03 | 13 |
| hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa012321 | Liver | Cirrhotic | Nucleotide metabolism | 39/2530 | 85/8465 | 1.27e-03 | 6.73e-03 | 4.15e-03 | 39 |
| hsa007701 | Liver | Cirrhotic | Pantothenate and CoA biosynthesis | 13/2530 | 21/8465 | 2.32e-03 | 9.90e-03 | 6.10e-03 | 13 |
| hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa012322 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa007702 | Liver | HCC | Pantothenate and CoA biosynthesis | 16/4020 | 21/8465 | 7.16e-03 | 1.97e-02 | 1.09e-02 | 16 |
| hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa012323 | Liver | HCC | Nucleotide metabolism | 59/4020 | 85/8465 | 3.30e-05 | 1.88e-04 | 1.04e-04 | 59 |
| hsa007703 | Liver | HCC | Pantothenate and CoA biosynthesis | 16/4020 | 21/8465 | 7.16e-03 | 1.97e-02 | 1.09e-02 | 16 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ENPP1 | SNV | Missense_Mutation | c.2351N>G | p.Tyr784Cys | p.Y784C | P22413 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD | |
| ENPP1 | SNV | Missense_Mutation | c.1603C>A | p.His535Asn | p.H535N | P22413 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ENPP1 | SNV | Missense_Mutation | c.2471N>C | p.Glu824Ala | p.E824A | P22413 | protein_coding | tolerated(0.26) | benign(0.115) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| ENPP1 | SNV | Missense_Mutation | c.2533N>T | p.Pro845Ser | p.P845S | P22413 | protein_coding | deleterious(0.01) | probably_damaging(0.934) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ENPP1 | SNV | Missense_Mutation | rs750660271 | c.1699N>G | p.Ile567Val | p.I567V | P22413 | protein_coding | deleterious(0.04) | probably_damaging(0.967) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| ENPP1 | SNV | Missense_Mutation | novel | c.547G>C | p.Val183Leu | p.V183L | P22413 | protein_coding | tolerated(0.11) | possibly_damaging(0.457) | TCGA-EW-A3U0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| ENPP1 | SNV | Missense_Mutation | rs373044722 | c.1441C>T | p.Arg481Trp | p.R481W | P22413 | protein_coding | deleterious(0) | probably_damaging(0.954) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ENPP1 | SNV | Missense_Mutation | rs202179867 | c.2531C>T | p.Thr844Met | p.T844M | P22413 | protein_coding | deleterious(0) | possibly_damaging(0.87) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ENPP1 | SNV | Missense_Mutation | c.2488N>T | p.His830Tyr | p.H830Y | P22413 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ENPP1 | SNV | Missense_Mutation | c.355N>G | p.Asn119Asp | p.N119D | P22413 | protein_coding | tolerated(0.49) | benign(0.085) | TCGA-IR-A3LF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |